Literature DB >> 8100582

Guidelines for the diagnosis of fragile X syndrome. National Fragile X Foundation.

B A Oostra1, P B Jacky, W T Brown, F Rousseau.   

Abstract

Direct DNA analysis of the fragile X mutation has become available with the isolation of DNA probes that detect the unstable DNA sequence containing the CGG repeat. We present the various alternatives of combinations of probes and enzymes that can be used for the diagnosis of fragile X syndrome. An overview is given of all the different available probes. A different protocol is presented for postnatal and prenatal diagnosis of fragile X syndrome. This includes Southern blot analysis as well as direct analysis of the CGG repeat by PCR amplification. We discuss the role of constitutional cytogenetic analysis in the diagnosis of mentally retarded subjects and cytogenetic analysis for the diagnosis of fragile X syndrome.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8100582      PMCID: PMC1016379          DOI: 10.1136/jmg.30.5.410

Source DB:  PubMed          Journal:  J Med Genet        ISSN: 0022-2593            Impact factor:   6.318


  20 in total

1.  Adjuvant systemic therapy for early breast cancer.

Authors: 
Journal:  Lancet       Date:  1992-01-04       Impact factor: 79.321

2.  Guidelines for the preparation and analysis of the fragile X chromosome in lymphocytes.

Authors:  P B Jacky; Y R Ahuja; K Anyane-Yeboa; W R Breg; N J Carpenter; U G Froster-Iskenius; J P Fryns; T W Glover; K H Gustavson; S F Hoegerman
Journal:  Am J Med Genet       Date:  1991 Feb-Mar

3.  Prenatal diagnosis of fragile X syndrome.

Authors: 
Journal:  Lancet       Date:  1991-10-12       Impact factor: 79.321

4.  Mapping of DNA instability at the fragile X to a trinucleotide repeat sequence p(CCG)n.

Authors:  E J Kremer; M Pritchard; M Lynch; S Yu; K Holman; E Baker; S T Warren; D Schlessinger; G R Sutherland; R I Richards
Journal:  Science       Date:  1991-06-21       Impact factor: 47.728

5.  Prenatal diagnosis of fragile X syndrome by direct detection of the unstable DNA sequence.

Authors:  G R Sutherland; A Gedeon; L Kornman; A Donnelly; R W Byard; J C Mulley; E Kremer; M Lynch; M Pritchard; S Yu
Journal:  N Engl J Med       Date:  1991-12-12       Impact factor: 91.245

6.  Identification of a gene (FMR-1) containing a CGG repeat coincident with a breakpoint cluster region exhibiting length variation in fragile X syndrome.

Authors:  A J Verkerk; M Pieretti; J S Sutcliffe; Y H Fu; D P Kuhl; A Pizzuti; O Reiner; S Richards; M F Victoria; F P Zhang
Journal:  Cell       Date:  1991-05-31       Impact factor: 41.582

7.  On some technical aspects of direct DNA diagnosis of the fragile X syndrome.

Authors:  F Rousseau; D Heitz; V Biancalana; I Oberlé; J L Mandel
Journal:  Am J Med Genet       Date:  1992 Apr 15-May 1

8.  Variation of the CGG repeat at the fragile X site results in genetic instability: resolution of the Sherman paradox.

Authors:  Y H Fu; D P Kuhl; A Pizzuti; M Pieretti; J S Sutcliffe; S Richards; A J Verkerk; J J Holden; R G Fenwick; S T Warren
Journal:  Cell       Date:  1991-12-20       Impact factor: 41.582

9.  Fragile X syndrome: genetic localisation by linkage mapping of two microsatellite repeats FRAXAC1 and FRAXAC2 which immediately flank the fragile site.

Authors:  R I Richards; K Holman; H Kozman; E Kremer; M Lynch; M Pritchard; S Yu; J Mulley; G R Sutherland
Journal:  J Med Genet       Date:  1991-12       Impact factor: 6.318

10.  Direct diagnosis by DNA analysis of the fragile X syndrome of mental retardation.

Authors:  F Rousseau; D Heitz; V Biancalana; S Blumenfeld; C Kretz; J Boué; N Tommerup; C Van Der Hagen; C DeLozier-Blanchet; M F Croquette
Journal:  N Engl J Med       Date:  1991-12-12       Impact factor: 91.245

View more
  23 in total

1.  FMR1 haplotype analyses among Indians: a weak founder effect and other findings.

Authors:  Deepti Sharma; Meena Gupta; B K Thelma
Journal:  Hum Genet       Date:  2002-12-14       Impact factor: 4.132

2.  Rapid antibody test for prenatal diagnosis of fragile X syndrome on amniotic fluid cells: a new appraisal.

Authors:  R Willemsen; F Los; S Mohkamsing; A van den Ouweland; W Deelen; H Galjaard; B Oostra
Journal:  J Med Genet       Date:  1997-03       Impact factor: 6.318

3.  Cost effectiveness of DNA diagnosis for four monogenic diseases.

Authors:  A A van der Riet; B A van Hout; F F Rutten
Journal:  J Med Genet       Date:  1997-09       Impact factor: 6.318

4.  Screening and diagnosis for the fragile X syndrome among the mentally retarded: an epidemiological and psychological survey. Collaborative Fragile X Study Group.

Authors:  B B de Vries; A M van den Ouweland; S Mohkamsing; H J Duivenvoorden; E Mol; K Gelsema; M van Rijn; D J Halley; L A Sandkuijl; B A Oostra; A Tibben; M F Niermeijer
Journal:  Am J Hum Genet       Date:  1997-09       Impact factor: 11.025

5.  Mental status of females with an FMR1 gene full mutation.

Authors:  B B de Vries; A M Wiegers; A P Smits; S Mohkamsing; H J Duivenvoorden; J P Fryns; L M Curfs; D J Halley; B A Oostra; A M van den Ouweland; M F Niermeijer
Journal:  Am J Hum Genet       Date:  1996-05       Impact factor: 11.025

Review 6.  Fragile X syndrome.

Authors:  A E Donnenfeld
Journal:  Indian J Pediatr       Date:  1998 Jul-Aug       Impact factor: 1.967

Review 7.  The fragile X syndrome.

Authors:  A T Hoogeveen; B A Oostra
Journal:  J Inherit Metab Dis       Date:  1997-06       Impact factor: 4.982

8.  Aberrant brain activation during gaze processing in boys with fragile X syndrome.

Authors:  Christa Watson; Fumiko Hoeft; Amy S Garrett; Scott S Hall; Allan L Reiss
Journal:  Arch Gen Psychiatry       Date:  2008-11

Review 9.  Fruit flies and intellectual disability.

Authors:  François V Bolduc; Tim Tully
Journal:  Fly (Austin)       Date:  2009-01-12       Impact factor: 2.160

10.  Longitudinal in vivo developmental changes of metabolites in the hippocampus of Fmr1 knockout mice.

Authors:  Da Shi; Su Xu; Jaylyn Waddell; Susanna Scafidi; Steven Roys; Rao P Gullapalli; Mary C McKenna
Journal:  J Neurochem       Date:  2012-11-07       Impact factor: 5.372

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.